VisionHealth, founded in 2017 and led by CEO Dr. Sabine Haeussermann, develops digital therapeutic support for respiratory diseases. The company focuses on improving inhaled drug therapy through its Kata® digital therapeutic, which uses augmented reality and the smartphone camera to provide immediate feedback and correction. VisionHealth develops solutions in cooperation with research institutions, selected industry partners, medical experts and IT specialists. The product aims to enable sustainable improvements to existing standard therapies for patients with chronic lung diseases like asthma and COPD. The company intends to use new funding to finance extended COPD and asthma studies and to prepare the market for Kata®. Planned next steps include pursuing EU and U.S. regulatory approval and a commercial launch of the Kata app in Germany and select European markets. VisionHealth GmbH develops digital therapy support for inhalation therapy aimed at improving treatment of chronic respiratory diseases. Its core product, the Kata app, is a medical device that assists and optimizes patients' drug inhalation therapy. The company works with research institutions, industry partners, medical experts and IT experts to create its solutions. Founded in 2017 and based in Garching, Germany, VisionHealth plans to complete regulatory approval of Kata as a Digital Health Application by BfArM under the German Digital Health Care Act (DVG). It intends to use the recent financing to run a health economic trial and complete the approval process to enable permanent reimbursement by German health insurers. The company plans to enter the German market and generate revenue by licensing Kata to pharmaceutical and medtech companies.

Total raised

$5M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2023